Previous close | 0.3300 |
Open | 0.3500 |
Bid | 0.4000 |
Ask | 0.4300 |
Strike | 26.00 |
Expiry date | 2024-09-20 |
Day's range | 0.3400 - 0.4200 |
Contract range | N/A |
Volume | |
Open interest | 9.75k |
Novavax stock is soaring on news the FDA set a deadline by which to approve or reject its COVID-19 vaccine.
The late-stage study will evaluate AbbVie's (ABBV) experimental antibody to treat patients with relapsed/refractory multiple myeloma who have received at least two lines of prior therapy.
Government advisers Wednesday said it’s time to update the recipe for the COVID-19 vaccines Americans will receive in the fall -- targeting a version of the ever-evolving coronavirus called JN.1. Moderna, Pfizer and Novavax all have tested doses updated to match the JN.1 variant that became dominant last winter. FDA’s advisers voted Wednesday that the next vaccine should come from the JN.1 “lineage” or family.